The Narrative That Built an Industry

LUMINA Counter-Narrative Analysis CN-001

You have likely heard this claim: depression is caused by a chemical imbalance in the brain, specifically a deficiency of serotonin. The logic is straightforward. Fix the chemistry, fix the mood. This framing has structured how millions of people understand their suffering since the early 1990s. It has shaped prescription patterns, therapeutic conversations, and the way distressed individuals narrate their own experience back to themselves.

In July 2022, researchers led by Joanna Moncrieff at University College London published a systematic umbrella review in Molecular Psychiatry examining the empirical basis for this claim. Their conclusion: "There is no consistent evidence of there being an association between serotonin and depression, and no support for the hypothesis that depression is caused by lowered serotonin activity or concentrations."

This was not a new finding. The hypothesis had been questioned for years in clinical literature. What made Moncrieff's review significant was its scope and its timing. The authors reviewed decades of neurobiological research across multiple evidence streams. The picture was consistent: no reliable evidence for a serotonin deficit in depression.

The gap between what was marketed to the public and what researchers understood is the substance of this analysis.

How the Narrative Took Hold

The serotonin theory emerged from genuine pharmacological observation. SSRIs do affect serotonin availability in the synapse. They do relieve depression for some people. From this fact, a causal story was constructed: the drugs work because depression is a serotonin deficiency.

This is a narrative error. A drug's mechanism of action does not prove it addresses the primary cause of an illness. Aspirin reduces fever, but fever is not an aspirin deficiency. The logic is appealingly simple, but it collapses under scrutiny.

What made this narrative stick was not clinical evidence. It was marketing infrastructure.

Direct-to-consumer advertising for antidepressants exploded after US regulatory changes in 1997. Spending grew from $166 million in 1993 to $4.2 billion by 2005. The message was consistent: you have a chemical imbalance; this medication corrects it; feeling better is neurochemically achievable.

The message was not entirely false. It was strategically incomplete.

The Institutional Mechanism

When the narrative faced serious challenge, the institutional response followed a recognisable pattern. A group of 36 researchers responded to Moncrieff's review with a rebuttal. Their rebuttal did not defend the version of the serotonin theory that had been marketed to millions. It defended a narrower, more qualified version that had never left specialist literature. The public had been told depression was a serotonin deficiency. The experts, when challenged, defended the claim that serotonin might be involved in some way in depression pathology.

The question is not who is right about the science. The question is what happened in the gap between what was marketed and what was meant.

The Structural Costs

The serotonin narrative foreclosed alternative explanations. If depression is a brain chemistry problem, then environmental stressors, relational patterns, structural inequality, and developmental trauma become secondary. This reorders what gets investigated, funded, and treated.

The financial entanglement is material. According to research by Cosgrove and colleagues (2024), 60 per cent of the panels that created the DSM-5-TR had financial relationships with pharmaceutical companies, totalling more than $14 million during 2016-2019. The global antidepressant market reached $18.7 billion in 2024. The boundary between generating knowledge and generating profit has become difficult to locate.

This is not a claim that antidepressants do not work. They do, for some people, in some contexts. This is a claim about how authority is exercised through narrative, and what it costs the people who absorb that narrative without the literacy to assess it.

This is a summary of LUMINA's first counter-narrative analysis. The complete CN-001 analysis, including the full DARVO mapping, institutional mechanism breakdown, evidence classification, withdrawal data, and complete source documentation, is available in the LUMINA Research Centre for registered members.

Read the full CN-001 analysis →

Key sources: Moncrieff et al. (2022) Molecular Psychiatry; Cosgrove et al. (2024) BMJ; Therapeutics Letter (2025)